|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's range||119.50 - 123.26|
|52-week range||98.94 - 135.89|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||45.38|
|Earnings date||23 Nov 2021|
|Forward dividend & yield||2.52 (1.94%)|
|Ex-dividend date||23 Sept 2021|
|1y target est||145.56|
The company released a discouraging business update after market hours on Friday, and its stock took it on the chin the following trading day. In that update, Medtronic said that a clinical trial of its Symplicity Renal Denervation System to lower blood pressure in hypertension patients will continue for an unspecified length of time. In Medtronic's words, the monitoring board "has recommended that clinical trial enrollment continue as planned, until the full, predefined sample size is reached."
The Baylis Medical buyout is expected to expand Boston Scientific's (BSX) electrophysiology and structural heart product offerings.